| Generic name | Tafasitamab-cxix |
| Brand name(s), other common name(s) | Monjuvi® |
| Drug type | CD19-directed cytolytic antibody |
| How the drug is given | For injection, for intravenous use |
Indications and Usage
Tafasitamab-cxix is approved in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Side effects needing medical attention
The most common adverse reactions are neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, fever, peripheral edema, respiratory tract infection, and decreased appetite.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.